STOCK TITAN

Exelixis (EXEL) Stock News

EXEL NASDAQ

Exelixis Inc. reports developments from its oncology business, including commercial performance for the cabozantinib franchise and clinical and regulatory updates across cancer programs. The company discovers, develops and commercializes cancer medicines, with CABOMETYX® (cabozantinib) as its flagship commercial product and COMETRIQ® also part of its cabozantinib portfolio.

Recurring updates include quarterly financial results, product revenue trends, financial guidance, pipeline milestones and investor conference presentations. Exelixis also discusses zanzalintinib, an investigational oral kinase inhibitor, and a broader pipeline of small molecules and biotherapeutics targeting additional tumor types and indications.

Rhea-AI Summary

Kernal Bio announced a partnership and investment from the Institute for Follicular Lymphoma Innovation to support development of KR-402.

The company expects the funding to accelerate preclinical development of its candidate for follicular lymphoma. The investment complements an earlier ARPA-H award of up to $48 million for KR-402. The candidate uses messenger RNA to generate engineered immune cells directly inside the body and is under development for B-cell malignancies and autoimmune diseases, including multiple sclerosis.

Kernal Bio appointed Kirsten Kester as Chief Business Officer and Sieun K. Barnes as Director of Process Development (CMC). Stuart Chaffee joined the board, with Carol O’Hear and Patrick Lundgren joining as board observers. New advisers are William H. Robinson, Thomas Dörner, Lawrence Steinman, Bruce Peacock and Craig Gibbs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.09%
Tags
none
-
Rhea-AI Summary

Exelixis (EXEL) management will participate in fireside chats at four investor conferences in November, with presentations available by webcast.

Scheduled appearances are Guggenheim in Boston on November 10, Stifel in New York City on November 11, UBS in London on November 17, and Jefferies in London on November 18. Webcasts and replays, available for at least 30 days, can be accessed through the company website’s Event Calendar.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
conferences
-
Rhea-AI Summary

Exelixis (EXEL) reported third-quarter 2026 revenue of $658.7 million, with higher product sales and GAAP earnings than a year earlier. Net product revenue rose to $604.9 million from $542.9 million. GAAP net income increased to $218.1 million from $193.6 million, and diluted earnings per share rose to $0.85 from $0.69.

The company maintained 2026 total revenue guidance of $2.500 billion–$2.550 billion and lowered its effective tax rate forecast to 16%–18% from 21%–23%. Guidance excludes potential zanzalintinib launch revenue. The FDA extended review of its colorectal cancer application by three months, setting a March 3, 2027 target action date. Exelixis expects STELLAR-304 kidney cancer trial results in the first quarter of 2027 and initiated additional colorectal and lung cancer trials. Repurchases under its May 2026 program reached $402.1 million by quarter-end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.82%
Tags
Rhea-AI Summary

Exelixis (EXEL) will release its third quarter 2026 financial results on October 29, 2026, after markets close.

Management will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results and provide a general business update. The webcast replay will remain available on the company’s website for one year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
earnings date
-
Rhea-AI Summary

Exelixis (Nasdaq: EXEL) will participate in fireside chats at three investor conferences in September: Wells Fargo 21st Annual Healthcare Conference on September 8 in Boston, Citi 2026 Biopharma Back to School Conference on September 9 in New York City, and Morgan Stanley 24th Annual Global Healthcare Conference on September 15 in New York City. All presentations will be webcast via the Event Calendar on the Investors & News section of www.exelixis.com, with replays available for at least 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.88%
Tags
conferences
-
Rhea-AI Summary

Exelixis (Nasdaq: EXEL) reported that the U.S. Court of Appeals for the Federal Circuit affirmed the 2024 Delaware District Court judgment upholding three patents covering the crystalline malate salt of cabozantinib (’439, ’440, ’015), preserving CABOMETYX market exclusivity. The court dismissed as moot an appeal on a separate low-impurity formulation patent (’349). Exelixis said the earliest MSN could launch a generic in the U.S. is January 15, 2030, subject to further appeals and litigation over another formulation patent (’039) expiring in February 2032.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
none
Rhea-AI Summary

Exelixis (Nasdaq: EXEL) reported second quarter 2026 total revenues of $628.7 million, up from $568.3 million a year earlier, driven by U.S. cabozantinib franchise net product revenues of $573.0 million and collaboration revenues of $55.7 million. GAAP diluted EPS was $0.82 versus $0.65, and non-GAAP diluted EPS was $0.91 versus $0.75.

Research and development expenses rose to $212.0 million and SG&A to $147.6 million, while GAAP net income increased to $212.1 million. For 2026, Exelixis updated guidance to total revenues of $2.50–$2.55 billion and net product revenues of $2.30–$2.35 billion, with reduced R&D expense guidance of $825–$875 million.

According to the company, cabozantinib collaboration royalties totaled $53.2 million, and the FDA is reviewing its NDA for zanzalintinib plus atezolizumab in previously treated metastatic colorectal cancer with a PDUFA target date of December 3, 2026. Multiple phase 2 and 3 trials of zanzalintinib across tumor types are ongoing or being initiated.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.94%
Tags
-
Rhea-AI Summary

Exelixis (Nasdaq: EXEL) will release its second quarter 2026 financial results on Wednesday, August 5, 2026, after the market close. Management will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT to review results and provide a business update.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
earnings date
-
Rhea-AI Summary

Exelixis (Nasdaq: EXEL) reported final overall survival (OS) results in the non-liver metastases (NLM) subgroup of the phase 3 STELLAR-303 trial of zanzalintinib plus atezolizumab versus regorafenib in previously treated metastatic colorectal cancer.

The NLM subgroup showed a non-statistically significant OS trend favoring the combination (HR 0.83; 95% CI 0.66–1.05; P=0.1185), with median OS of 15.9 vs 12.7 months. Safety was consistent with the overall population, with no new safety signals. STELLAR-303 previously met its other dual primary endpoint, showing a statistically significant OS benefit in the full ITT population. The FDA has accepted the NDA for this regimen, with a PDUFA target action date of December 3, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
Rhea-AI Summary

Exelixis (Nasdaq: EXEL) reported subgroup results from the phase 3 CABINET trial of CABOMETYX (cabozantinib) in previously treated advanced neuroendocrine tumors (NET) at ASCO 2026.

Cabozantinib reduced the risk of disease progression or death by 74% in non-functional and 60% in functional NET versus placebo and improved median progression-free survival across subgroups, with a safety profile consistent with prior experience.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.40%
Tags

FAQ

What is the current stock price of Exelixis (EXEL)?

Exelixis (EXEL) last closed at $64.63.

What is the market cap of Exelixis (EXEL)?

The market cap of Exelixis (EXEL) is approximately $15.8B.